Payload Information
General Information of This Payload
| Payload ID | PAY0AAMXQ |
|||||
|---|---|---|---|---|---|---|
| Name | TW202436324A+ADC-1.1+payload |
|||||
| Synonyms |
TW202436324A+ADC-1.1+payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C22H19FN4O2 |
|||||
| Isosmiles | O=C(NC1=C(N)C=C(F)C=C1)C2=CC=C(CNC(/C=C/C3=CN=CC=C3)=O)C=C2 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)
|
|||||
| InChIKey |
SZMJVTADHFNAIS-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
390.418 |
Polar area |
97.11 |
||
Complexity |
1001.663777 |
xlogp Value |
3.3848 |
|||
Heavy Count |
29 |
Rot Bonds |
6 |
|||
Hbond acc |
4 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Growth Rate | -50 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cellular activity | 0.04 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 0.05 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 0.07 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 0.072 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 0.084 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 0.117 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 0.142 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 0.353 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 1.22 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cell-based Percent Inhibition (%) | 1.62 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 1.62 | % |
Vero C1008 cells
|
Normal
|
||
| Cellular activity | 1.65 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 1.66 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cell-based Growth Rate | 100 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | 100 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | 100 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | 100 | % |
HEK-293T cells
|
Normal
|
||
| Cellular activity | 102.26 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cellular activity | 11.5 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cell-based Percent Inhibition (%) | 16.87 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 17.5 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 18.1 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 2.27 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 2.52 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 2.67 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 2.74 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 22.7 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 24.4 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 3.72 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cell-based Percent Inhibition (%) | 37.3 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 37.9 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 4.06 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 4.66 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 4.81 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 5 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 5.59 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 5.7 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 5.95 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 5.96 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 50 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cellular activity | 51 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 53.5 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 56.1 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 6.77 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cell-based Percent Inhibition (%) | 62.1 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 69.91 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 71.1 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 72.6 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 73.4 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Tumor Growth Inhibition (TGI) | 73.5 | % |
SKM-1 cells
|
Acute myeloid leukemia
|
||
| Cellular activity | 77.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 78.4 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 8.11 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 8.27 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cell-based Growth Rate | 82 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cellular activity | 84.7 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 87.5 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 88.5 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 88.85 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cellular activity | 9.77 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 90.3 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cell-based Percent Inhibition (%) | 90.9 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 93.5 | % |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Cellular activity | 93.9 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 95.1 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 96.6 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
ZR-75-1 cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
COLO-678 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1010 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1080 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1090 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 112 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1180 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1202 | nM |
Jurkat cells
|
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 122.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
HEL cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1340 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 140 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1490 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1500 | nM |
Jurkat cells
|
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 160 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 16000 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 163 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 167 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 167 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1682 | nM |
MIA PaCa-2 cells
|
Pancreatic undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1714 | nM |
PC-9 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1775 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
HEL cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 184 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 186 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1860 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1860 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 196 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 196 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 196.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1970 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2000 | nM |
U2OS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
NCI-H1650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2080 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2080 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2082 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 220 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2340 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 235 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 238.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 240 | nM |
NCI-H446 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2400 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2420 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 25000 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2620 | nM |
NCI-H441 cells
|
Lung papillary adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2623 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 263 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 265 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2650 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2790 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2890 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2900 | nM |
EBC-1 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29070 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 296 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3091 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3110 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 320 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3200 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 330 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3300 | nM |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3300 | nM |
MC-38 cells
|
Mouse colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 340 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 359 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3730 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 400 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 4000 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 4000 | nM |
Raji cells
|
EBV-related Burkitt lymphoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 4000 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 40000 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 432 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 449 | nM |
DOHH2 cells
|
Diffuse large B-cell lymphoma germinal center B-cell type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 450 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4515 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 455.84 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4570 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4660 | nM |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48.25 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 480 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4890 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 5000 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 50000 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 50000 | nM |
NCI-H292 cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 50000 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 50000 | nM |
SGC-7901 cells
|
Gastric carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 50000 | nM |
SK-N-SH cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 530 | nM |
DOHH2 cells
|
Diffuse large B-cell lymphoma germinal center B-cell type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 549 | nM |
SKM-1 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5570 | nM |
SKNO-1 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 560 | nM |
SU-DHL-2 cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 570 | nM |
CAKI-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5770 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 5800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 590.47 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6040 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 619 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 62.12 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 620 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6244 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 63.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 630 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 630 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 6300 | nM |
PANC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 6650 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 669 | nM |
ES-2 cells
|
Ovarian clear cell adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 67 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 690 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7160 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7200 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 733 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 747 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 750 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 760 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7800 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 783 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 7900 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 82.87 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 830 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8300 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 833 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8460 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 870 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 920 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 93 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 93.28 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9432 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 95 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9520 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 966.15 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 98.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9850 | nM |
A549 cells
|
Lung adenocarcinoma
|
Each Antibody-drug Conjugate Related to This Payload